Ticagrelor And PrEconditioning in patients with stable coronaRy artery diSease: a randomized pilot trial (TAPER-S trial) Ticagrelor e precondizionamento in pazienti con malattia coronarica stabile: studio pilota randomizzato (Studio TAPER-S)

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 09 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clopidogrel (Primary) ; Ticagrelor (Primary) ; Aspirin
Indications Coronary artery disease
Focus Therapeutic Use
Acronyms TAPER-S

Most Recent Events

28 Aug 2023 Results assessing whether ticagrelor, as compared to clopidogrel, could enhance ischemic preconditioning in patients with stable CAD undergoing PCI presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
10 Mar 2022 Status changed from completed to discontinued.
13 Nov 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight